Diagenic - 500 Beiträge pro Seite

[vammi]

Man sollte mal www.diagenic.com anschauen. diese kleine osloer firma entwickelt ein verfahren um alzheimer über genexpressions-signaturen im blut FRÜHZEITIG zu erkennen. eine blutbestimmung ist weniger invasiv daher hochinteressant verglichen mit liquor-bestimmung

diagenic plant noch in diesem jahr das diagnostische system auf die beine zu stellen. sollte dies gelingen, steht die firma vor einer neubewertung. derzeit ist diagenic noch mehr als unentdeckt und wird in deutschland kaum gehandelt.

[vammi]

hallo, ich scheine hier wohl selbstgespräche zu führen. das könnte sich bald ändern

bei diagenic übernimmt ein mann von abbot die leitung der firma diagenic ab januar 2007. damit steigen die chancen für die markteinführung der blut-genexpressionssignaturen für alzheimer und brustkrebs.

Press Release Source: DiaGenic ASA DiaGenic ASA

Diagenic ASA Appoints Erik Christensen as Managing Director
Tuesday October 3, 5:04 am ET
Company Intends to Become Key Molecular Dx Player

OSLO, Norway--(BUSINESS WIRE)--DiaGenic ASA (OSEIAG) today announced that it has appointed Erik Christensen MD PhD (50) as their new Managing Director. Christensen is currently Country Manager of the Diagnostics Division of Abbott Norway and will start in his new role on January 1, 2007. Current Managing Director and co-founder Dr Anders Lonneborg will take up the position of Scientific Director. Christensen comes to DiaGenic with a strong background in international diagnostics development, marketing and strategy as well as an understanding of the overall diagnostics pathway through previous research and clinical roles. This combination of experience perfectly matches DiaGenic's needs - the company recently presented breakthrough data on its gene expression signature test for Alzheimer's disease (AD) and is on track to have validated assay designs for both AD and breast cancer ready for large scale clinical trials by the end of the year.

ADVERTISEMENT
Christensen commented: "I have followed DiaGenic's progress with great interest and now see the opportunity to help develop DiaGenic into an important and significant player internationally in the molecular diagnostics field. My experience runs from research, through clinical to commercialisation and it is with this broad knowledge base I will develop the company further."

DiaGenic Chairman Haakon Saeteroy also welcomed the appointment: "DiaGenic is now moving into an exciting phase of the company's development with our first two assays approaching clinical trials. Erik Christensen has the experience and knowledge needed to ensure we exploit this potential successfully, and we have also been impressed with the way his vision for the DiaGenic matches ours - namely to become a leading player in the new molecular diagnostics market."

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com


Contact:

Corporate Inquiries:
DiaGenic ASA
Haakon Saeteroy, [phone]
[e-mail]
or
Media Inquiries:
4Bio
Richard Hayhurst, [phone]
Mobile: [phone]
[e-mail]

Source: DiaGenic ASA DiaGenic ASA

[vammi]

immer noch keine meinung zu diagenic?
na gut, ich poste mal einfach die news wenn sie kommen und hoffe niemanden allzu sehr zu langweilen

Four experts joining Diagenic team
(2006-11-09 12:05)
Four leading international breast cancer experts have joined Oslo company Diagenic’s scientific advisory board. At the same time, Diagenic also confirmed that the first prototype of its unique gene expression signature test for breast cancer is on track.

By Alannah Eames

Martine Piccart and Christos Sotiriou of the Université Libre de Bruxelles, Ann-Lise Borresen-Dale of the Norwegian Radium Hospital and Alan Hollingsworth of the Mercy Women’s Center in Oklahoma city will join Diagenic’s scientific advisory board.

Diagenic’s signature test for breast cancer uses peripheral blood as sample material and this non-invasive approach has created widespread interest in the breast cancer research community.

“We are delighted to have attracted leading names such as Martine Piccart, Christos Sotiriou and Alan Hollingsworth to join our longstanding collaborator Anne-Lise Børresen-Dale,” commented Diagenic’s CEO, Anders Lönneborg.

“They are unanimous on the need for earlier and improved diagnosis of breast cancer and will provide invaluable advice and guidance as we approach the clinical trials phase in our development.”

Currently Diagenic is finalizing its first prototype by comparing performance of selected gene probes for the development of breast cancer gene expression signature on the ABI TaqMan and GE Codelink low density array platforms.